Statistics from Altmetric.com
Is there an association between treatment with antipsychotic drugs and the risk of hyperglycaemia in older persons with pre-existing diabetes?
Participants were 13 817 people aged ≥66 years (mean age 78 years) with a prior diagnosis of diabetes and who had started treatment with an antipsychotic drug between April 2002 and March 2006. The cohort entry date was the date of the first prescription with an antipsychotic. Cases were defined as those who were hospitalised for hyperglycaemia, and each was matched with up to 10 controls for the nested case–control comparison. Date of event was defined as the index date, and drug use was classified in relation to this date. Controls were assigned the same index date as the case to which they were matched. Participants receiving dialysis or palliative care or residing in long-term care facilities were excluded. People in the cohort were stratified by prescription records for their diabetes in the 180 days before cohort entry and grouped (insulin treated, oral hypoglycaemic agent no insulin and no treatment).
Canada; recruitment 2002–2006.
Prescription antipsychotic drug use; drug …
Sources of funding Canadian Institutes of Health Research, Canadian Diabetes Association ad Ontario Ministry of Health.
Competing interests DCH has received research grants from Pfizer, BMS, Johnson and Johnson, Takeda, Solvay, Eli Lilly, NIMH, McCall MacBain Foundation, Stanley Foundation; honorarium for lectures from BMS, Pfizer, Janssen; honorarium for advisory boards from Janssen, Solvay, Wyeth, BMS, Pfizer.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.